This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1533317508325093v1 23/6/571    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chan, A. Articles by Shea, T. B. Search for Related Content PubMed PubMed Citation Articles by Chan, A. Articles by Shea, T. B. Pubmed/NCBI databases Medline Plus Health Information Alzheimer's Disease Dietary Supplements Vitamins Social Bookmarking                         What's this?

Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-Year, Open-Label Pilot Study With an 16-Month Caregiver Extension

^* To whom correspondence should be addressed. E-mail: Thomas_Shea{at}uml.edu.

	Abstract

We examined the efficacy of a vitamin/nutriceutical formulation (folate, vitamin B6, alpha-tocopherol, S-adenosyl methionine, N-acetyl cysteine, and acetyl-L-carnitine) in a 12-month, open-label trial with 14 community-dwelling individuals with early-stage Alzheimer’s disease. Participants improved in the Dementia Rating Scale and Clock-drawing tests (Clox 1 and 2). Family caregivers reported improvement in multiple domains of the Neuropsychiatric Inventory (NPI) and maintenance of performance in the Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADL). Sustained performance was reported by caregivers for those participants who continued in an 16-month extension. Performance on the NPI was equivalent to published findings at 3 to 6 months for donepezil and exceeded that of galantamine and their historical placebos. Participants demonstrated superior performance for more than 12 months in NPI and ADL versus those receiving naproxen and rofecoxib or their placebo group. This formulation holds promise for treatment of early-stage Alzheimer’s disease prior to and/or as a supplement for pharmacological approaches. A larger, placebo-controlled trial is warranted.

First published on December 1, 2008, doi:10.1177/1533317508325093

American Journal of Alzheimer's Disease and Other Dementias® 2009;23:571.

A more recent version of this article appeared on January 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?